Recon: Trump Urges Opioid Action

• Trump urges lawsuit against opioid companies, tougher sentences for dealers (Reuters) (Law360-$) (CBS News) (US News)
• Uber launches Uber Health, a B2B ride-hailing platform for healthcare (TechCrunch) (Modern Healthcare) (The Atlantic) (USA Today)
• Mylan to introduce two new HIV combination treatments in the U.S. (MarketWatch) (StreetInsider)
• Google signed a key deal with a $9.5 billion device maker to save healthcare from a 'world of ignorance' (Business Insider) (FierceBiotech)
• Kentucky could become the first state to tax opioid prescriptions (Stat News) (The Washington Post)
• Helix, Competing With Ancestry And 23andMe, Raises $200 Million For Marketing War (Forbes) (MobiHealthNews)
• Regeneron's Eylea Inflammation Risk Tied to Drug Syringes (Bloomberg) (FiercePharma)
• FDA asks online retailers Amazon, Ebay, Walmart to restrict anti-diarrheal medication used by opioid addicts (Washington Examiner) (The Washington Times)

• Asian investor commits $15M to launch new protein degradation biotech startup Cullgen out of UNC (Endpoints News)
• Pfizer, Merck KGaA nab NICE's favor for Bavencio in Merkel cell carcinoma (Fierce)
• Lilly underlines what's at stake in Brexit talks (The Pharma Letter-$)
• Overwhelmed health system to blame for Kenya hospital mix-up: doctors (Reuters)
• Indonesia's first biomedicine factory opens (Nikkei Asian Review) (FiercePharma)
• Why Oppenheimer Global fund is focusing on biotech as rates rise (Reuters)
• EU-US FDA mutual recognition of inspections of medicines manufacturers enters operational phase (EC) (Focus)

• Remarks by Dr. Gottlieb on Enhancing Drug Distribution Security (FDA)
• Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries (Stat News-$)
• Valeant settles Solodyn pay-for-delay litigation for $58 million (Reuters) (Law360-$)
• McCaskill seeks to end tax breaks for consumer drug ads (Stat News-$)
• Amid a boisterous fundraising week, BioMedPartners airs $107M biotech fund (Endpoints News)
• Despite ‘responsible’ price, Regeneron drug kept out of many patients’ hands by payers (Stat News-$)
• Express Scripts Turns To Dogs And Cats Amid Flat Prescription Growth (Forbes)
• Beacon and Takeda initiate multi-year drug discovery collaboration (The Pharma Letter-$)
• Oregon Drug Price Transparency Bill Heads to Senate (BioCentury)

• Roche, Ionis herald a big win in early-stage Huntington’s disease trial, demonstrate disease modifying potential (Endpoints News)
• Verona jumps as midphase cystic fibrosis data dial up hopes (FierceBiotech)
• Roche, Ionis hail Huntington's success, plan pivotal trial (FierceBiotech)
• Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies (Press)
• Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients (Press)
• Nightingale Health announces strategic collaboration with PerkinElmer (The Daily Telescope)
• Hisamitsu totes positive Phase III data for transdermal PD therapy (The Pharma Letter-$)
• Stem cells shed light on potential anti-Alzheimer’s compound (FierceBiotech)
• A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics (JAMA)
• FDA to review Dupixent sBLA in asthma (The Pharma Letter-$)
• IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease (Press)
• CTTI continues to address barriers to single IRB adoption: latest expert meeting summary (CTTI)

• Zimmer Biomet loses Pa. state appeal in $16m knee implant loss (MassDevice)
• 3rd Circ. Nixes Part Of 'Hybrid' Medical Device Suit (Law360-$)
• PTAB Upholds Eye Treatment Tool Patent (Law360-$)
• InterSystems and Rhode Island Quality Institute Deliver Designee Alerts for Patient Empowerment (Press)
• Gelesis raises $30M to gear up for weight loss launch (FierceBiotech)
• Philips, Hologic ink mammography deal (MassDevice) (Press)
• Covance Enters into Strategic Technology Agreement with GSK (Press)
• Biocartis grabs lab space, staff from Johnson & Johnson to fuel U.S. expansion (FierceBiotech) (Press)
• ALFA receives another US FDA 510(k) clearance for Simple Cup multi-drug test with Driven Flow (Press)
• How LensCrafters is using iPads to reinvent the eye exam (MobiHealthNews)
• Precision Health AI Launches Eureka HealthTM Oncology AI Platform, First of Its Kind “System of Intelligence” Which Delivers Data-Driven Insights to the Cancer Care Community (Press)
• Samsung Presents its Latest Medical Equipment and Healthcare Solutions at the 2018 European Congress of Radiology (Press)
• FDA approves BD Onclarity HPV Assay (FDA)

• Alphabet Loses Top AI Researcher at Anti-Aging Unit Calico (Bloomberg-$) (Endpoints News)
• 'Revolving Door' At DEA Faces Scrutiny In Opioid MDL (Law360-$)
• Travis Kalanick joins board of medical software company (Axios) (Bloomberg)
• How the U.S. military might help answer a critical question about the flu vaccine (Stat News-$)
• Express Scripts Needs to Get Vertical (Bloomberg)
• Senate plans 340B oversight hearings as transparency push mounts (Modern Healthcare)
• FDA seeks comment on Post-Marketing Pediatric-Focused Product Safety Reviews (FDA)

• FDA Advisory Committee Calendar

• Science Says: Why Europe still has so many measles outbreaks (AP News)
• Supply chain commitment to tackling problem of medicine shortages (Press)

• India warns medical device makers on pricing data (MassDevice)
• Axio Bio gets USFDA nod for first aid product Axiostat (India Today) (MassDevice)

• Third death in rockmelon listeria outbreak (The West Australian)
• Endometriosis research allocated $2.5 million in Government funding (ABC News)

• They cost us billions and they can kill: Counterfeit drugs are invading Canada (Financial Post)
• WeedMD to Secure Dealer’s License from Health Canada as a Next Step in its R&D Strategy (Press)
• Canada's Pharmascience Renews Agreement With CDMO Saneca Pharma (Pharmaceutical Processing)
• Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved Trulance from Synergy Pharmaceuticals (Press)
• Innovus Pharma’s AllerVarx Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis (Press)

• How a society gala was used to sell young-blood transfusions to baby boomers desperate to cheat death (Stat News)
• As Surgery Centers Boom, Patients Are Paying With Their Lives (Kaiser Health News)
• The Challenge of Doctor-Patient Relations in the Internet Age (The New York Times)
• Worst of bad US flu season is over as illnesses decline (AP News)
• We need to rethink mental health laws. But not because of mass shootings. (The Washington Post)